Humoral Immune Response After Intravitreal But Not After Subretinal AAV8 in Primates and Patients
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Purpose: To study longitudinal changes of anti-drug antibody (ADA) titers to recombinant adeno-associated virus serotype 8 (rAAV8) capsid epitopes in nonhuman primates (NHP) and patients. Methods: Three groups of six NHP each received subretinal injections (high dose: 1 × 1012 vector genomes [vg], low dose: 1 × 1011 vg, or vehicle only). Four additional animals received intravitreal injections of the high dose (1 × 1012 vg). Three patients received 1 × 1010 vg as subretinal injections. ELISA quantified ADA levels at baseline and 1, 2, 3, 7, 28, and 90 days after surgery in NHP and at baseline and 1, 3, and 6 months after surgery in patients. Results: Two out of 22 animals lacked ADA titers at baseline and developed low ADA titers toward the end of the study. Titers in the low-dose group stayed constant, while two of six animals from the high-dose group developed titers that rose beyond the range of the assay. All animals from the intravitreal control group showed a rise in ADA titer by day 7 that peaked at day 28. Preliminary data from the clinical trial (NCT02610582) show no humoral immune response in patients following subretinal delivery of 1 × 1010 vg. Conclusions: No significant induction of ADA occurred in NHP when mimicking the clinical scenario of subretinal delivery with a clinical-grade rAAV8 and concomitant immunosuppression. Likewise, clinical data showed no humoral immune response in patients. In contrast, intravitreal delivery was associated with a substantial humoral immune response. Subretinal delivery might be superior to an intravitreal application regarding immunologic aspects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Intravitreal delivery of adeno-associated virus (AAV) vectors offers a promising, minimally invasive strategy for retinal gene therapy, but remains limited by dose-dependent intraocular inflammation.”
From Intravitreal AAV vector delivery induces integrin-dependent ocular inflammation, complement activation, and antiviral and DNA damage responses (2026) · cites this paper as [11]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many studies have shown minimal to absent humoral response to antigens delivered to this space.13,74,75”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other studies also found that gene transduction was achievable if injected in the subretinal space even if the subjects have neutralizing antibodies.74,92”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As expected from previous reports (11), most animals developed anti-AAV2.7m8 IgG antibodies, which were detectable in both VH and AH samples independent of the uveitis scores (Figure 1E).”
From Intravitreal AAV vector delivery induces integrin-dependent ocular inflammation, complement activation, and antiviral and DNA damage responses (2026) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the presence of pre-existing neutralizing antibodies to AAV does not appear to correlate with a higher risk of retinal inflammation or reduced therapeutic efficacy, provided that the AAV vector is delivered via the subretinal route.27, 28, 29”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [28]
Experimental — accuracy not yet measured
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 2×
“As such, clinical trials in hemophilia patients have shown that circulating antibodies can effectively inhibit transduction even at low titers, and that AAV-directed CD8þ cells target and remove successfully transduced hepatocytes as virus-infected cells.(5) In contrast to the treatment for hemophilia, where AAV vecto…”
BackgroundMethodSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955 · cited 1×
“It may, however, become relevant in a scenario of multiple injections and/or intravitreal applications.(3,18) Intravitreal may be considered the preferred route of administration when targeting inner layers or wide areas of the retina.”
BackgroundHauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954 · cited 1×
“One study reported a single case in which anti-capsid antibodies emerged in a functional assay around day 14 but declined later,(6) and in another study some anti-capsid antibody titers increased toward day 90 but were still low compared to the overall mean.(8) Amado et al.”
ResultWorldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Bennett, J., Ashtari, M., Wellman, J., Marshall, K. A., Cyckowski, L. L., Chung, D. C., McCague, S., Pierce, E. A., Chen, Y., Bennicelli, J. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002865 · Cited by 395 · cited 1×
“This is in line with the observation that readministration of subretinal AAV (to the contralateral eye) in three adult patients did not lead to a rise in antibody titer.(11) Importantly, though, intravitreal delivery of AAV2 has been shown to induce humoral immune response in mice and block transduction in subsequent…”
ResultImprovement and Decline in Vision with Gene Therapy in Childhood Blindness
Jacobson, S. G., Cideciyan, A. V., Roman, A. J., Sumaroka, A., Schwartz, S. B., Heon, E., & Hauswirth, W. W. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412965 · Cited by 372
Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents
Calcedo, R., Morizono, H., Wang, L., McCarter, R., He, J., Jones, D., Batshaw, M. L., & Wilson, J. M. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05107-11 · Cited by 345 · cited 1×
“Through contact with wild-type AAV, humans develop antibodies against the different serotypes in their first years of life.(15,16) Depending on the study, seroprevalence for AAV8 ranges from 15% to 30% of the population (AAV2: 30%– 60%)(16,17) to 82% in Asian adult humans (AAV2: 97%).”
Background
Research works printed but not linked: 1
- [17]17. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adenoassociated viruses. J Infect Dis . 2009;199:381-390.
Cited by
Bucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Self-citationClinical Perspective: Treating RPE65-Associated Retinal Dystrophy
Maguire, A. M., Bennett, J., Aleman, E. M., Leroy, B. P., & Aleman, T. S. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.029 · Cited by 184
Yiu, G., Chung, S. H., Mollhoff, I. N., Nguyen, U. T., Thomasy, S. M., Yoo, J., Taraborelli, D., & Noronha, G. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.002 · Cited by 153
Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders
Pavlou, M., Schön, C., Occelli, L. M., Rossi, A., Meumann, N., Boyd, R. F., Bartoe, J. T., Siedlecki, J., Gerhardt, M. J., Babutzka, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013392 · Cited by 135
“With regard to the eye, only a transient immune response to intraocular vector delivery has been observed so far, which did not limit treatment success (Reichel et al, 2018; Rabinowitz et al, 2019).”
BackgroundSelf-citationImmunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Yang, T., Braun, M., Lembke, W., McBlane, F., Kamerud, J., DeWall, S. L., Tarcsa, E., Fang, X., Hofer, L., Kavita, U., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.018 · Cited by 136
Quinn, P. M., Buck, T. M., Mulder, A. A., Ohonin, C., Alves, C. H., Vos, R. M., Bialecka, M., van Herwaarden, T., van Dijk, E. H. C., Talib, M., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.03.002 · Cited by 97
Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases
Kansara, V., Muya, L., Wan, C.-R., & Ciulla, T. A. (2020) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2019.0126 · Cited by 84
“unlike the subretinal space, NAbs against AAVs can access the vitreous, which may induce humoral immune response, diminish therapeutic response, and increase safety risks.(17) These potential limitations of intravitreal gene delivery may be addressed by techniques such as ‘‘directed evolution’’ and ‘‘rational design’’…”
BackgroundDevelopment of retinal atrophy after subretinal gene therapy with voretigene neparvovec
Reichel, F. F., Seitz, I. P., Wozar, F., Dimopoulos, S., Jung, R., Kempf, M., Kohl, S., Kortüm, F. C., Ott, S., Pohl, L., et al. (2022) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-321023 · Cited by 84
Self-citationOcular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses
Ghoraba, H. H., Akhavanrezayat, A., Karaca, I., Yavari, N., Lajevardi, S., Hwang, J., Regenold, J., Matsumiya, W., Pham, B., Zaidi, M., et al. (2022) · Clinical Ophthalmology · doi:10.2147/opth.s364200 · Cited by 76
“Other studies also found that gene transduction was achievable if injected in the subretinal space even if the subjects have neutralizing antibodies.(74,92) This beneficial immune response has raised the question of whether it is better not to use steroids with a subretinal injection, as this would theoretically negat…”
BackgroundThe future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery
Ross, M., & Ofri, R. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.306063 · Cited by 67
“These include innate, humoral and cellular immunity that may affect both the safety and efficacy of gene therapy (Reichel et al., 2017, 2018; Colella et al., 2018).”
BackgroundAchromatopsia: Genetics and Gene Therapy
Michalakis, S., Gerhardt, M. J., Rudolph, G., Priglinger, S. G., & Priglinger, C. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00565-z · Cited by 78
“Transient subclinical induction of inflammatory markers has also been reported [87, 95].”
BackgroundSelf-citationSystemic and local immune responses to intraocular AAV vector administration in non-human primates
Ail, D., Ren, D., Brazhnikova, E., Nouvel-Jaillard, C., Bertin, S., Mirashrafi, S. B., Fisson, S., & Dalkara, D. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.011 · Cited by 61
“Hence, intravitreal AAV injections are expected to be more immunogenic than subretinal injections.(18,34,35) A study showed that an intravitreal (IVT) injection in one eye results in an immune response in the contralateral eye.”
BackgroundCiulla, T. A., Hussain, R. M., Berrocal, A. M., & Nagiel, A. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1740676 · Cited by 59
Host immune responses after suprachoroidal delivery of AAV8 in nonhuman primate eyes
Chung, S. H., Mollhoff, I. N., Mishra, A., Sin, T.-N., Ngo, T., Ciulla, T., Sieving, P., Thomasy, S. M., & Yiu, G. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.281 · Cited by 57
Chan, Y. K., Dick, A. D., Hall, S. M., Langmann, T., Scribner, C. L., Mansfield, B. C., & for the Ocular Gene Therapy Inflammation Working Group (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.4.3 · Cited by 56
Chandler, L., Yusuf, I., McClements, M., Barnard, A., MacLaren, R., & Xue, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144972 · Cited by 49
“On the other hand, intravitreal administration of AAV appears to induce a significantly greater level of anti-AAV antibody response [122] and is more prone to antibody-mediated reduction of AAV transduction over repeated treatments [123].”
BackgroundThe cGMP Pathway and Inherited Photoreceptor Degeneration: Targets, Compounds, and Biomarkers
Tolone, A., Belhadj, S., Rentsch, A., Schwede, F., & Paquet‐Durand, F. (2019) · Genes · doi:10.3390/genes10060453 · Cited by 51
“Currently, the standard route of administration for retinal drugs, such as anti-VEGF medications, is multiple dosing through intravitreal injection [89,94], while in the case of single-dose, gene therapeutic agents subretinal injection is the preferred technique [95].”
MethodOcular delivery of CRISPR/Cas genome editing components for treatment of eye diseases
Yu, W., & Wu, Z. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.011 · Cited by 50
Hammadi, S., Tzoumas, N., Ferrara, M., Meschede, I. P., Lo, K., Harris, C., Lako, M., & Steel, D. H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082870 · Cited by 44
Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina
Chandler, L. C., McClements, M. E., Yusuf, I. H., Martinez-Fernandez de la Camara, C., MacLaren, R. E., & Xue, K. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.05.011 · Cited by 43
Retinal Dystrophies and the Road to Treatment: Clinical Requirements and Considerations
Talib, M., & Boon, C. J. F. (2020) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000290 · Cited by 41
Tummala, G., Crain, A., Rowlan, J., & Pepple, K. L. (2021) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.62.2.41 · Cited by 36
“Similar to the results in our study, previous work by Reichel et al. 23 in NHPs identified evidence of a robust adaptive immune response developing 7 days after the injection of rAAV8.hCNGA3 in animals with baseline AAV8 seropositivity.”
Sobh, M., Lagali, P. S., Ghiasi, M., Montroy, J. R., Dollin, M. L., Hurley, B. R., Leonard, B. C., Dimopoulos, I. S., Lafreniere, M., Fergusson, D. A., et al. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.11.24 · Cited by 38
Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway
Dreismann, A. K., Hallam, T. M., Tam, L. C. S., Nguyen, C. V., Hughes, J. P., Ellis, S., & Harris, C. L. (2022) · Immunological Reviews · doi:10.1111/imr.13149 · Cited by 36
Ocular Inflammation and Treatment Emergent Adverse Events in Retinal Gene Therapy
Mehta, N., Robbins, D. A., & Yiu, G. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000366 · Cited by 33
The Blunt End: Surgical Challenges of Gene Therapy for Inherited Retinal Diseases
Davis, J. L. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.08.038 · Cited by 30
Gene-based therapeutics for acquired retinal disease: opportunities and progress
Tan, T.-E., Fenner, B. J., Barathi, V. A., Tun, S. B. B., Wey, Y. S., Tsai, A. S. H., Su, X., Lee, S. Y., Cheung, C. M. G., Wong, T. Y., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.795010 · Cited by 26
“Multiple studies in both non-human primates and humans have demonstrated that delivery of viral vectors into the vitreous cavity results in activation of the adaptive immune system, and triggers a significant humoral response (Kotterman et al., 2015; Reichel et al., 2018).”
BackgroundOcular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions
Banou, L., Sarrafpour, S., Teng, C. C., & Liu, J. (2024) · The Yale Journal of Biology and Medicine · doi:10.59249/hwid7537 · Cited by 29
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
“In contrast, subretinal gene therapy appears to induce NAb formation only infrequently in clinical trials and pre-clinical studies (Rakoczy et al., 2015; Reichel et al., 2018; Xue et al., 2018; Fischer et al., 2020).”
Self-citationKansara, V. S., Cooper, M. J., Sesenoglu‐Laird, O., Muya, L. W., Moen, R. C., & Ciulla, T. A. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.13.21 · Cited by 25
Ku, C. A., Wei, L. W., & Sieving, P. A. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041288 · Cited by 27
Tobias, P., Philipp, S. I., Stylianos, M., Martin, B., Barbara, W., Felix, R., Alexander, O. G., Eberhart, Z., Marius, U., Birgit, K., et al. (2019) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2018.188 · Cited by 23
Self-citationAn optimized treatment protocol for subretinal injections limits intravitreal vector distribution
Reichel, F. F. L., Wozar, F., Seitz, I., Ochakovski, A., Bartz-Schmidt, K. U., Peters, T., & Fischer, M. D. (2021) · Ophthalmology Science · doi:10.1016/j.xops.2021.100050 · Cited by 22
“In addition, comparative studies, where the vector was delivered either to the intravitreal space or to the subretinal space have shown that the subretinal space has the added benefit of limiting the systemic biodistribution and providing greater immune privilege.(9,10) We investigated how much of the vector solution…”
BackgroundSelf-citationMalvasi, M., Casillo, L., Avogaro, F., Abbouda, A., & Vingolo, E. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813756 · Cited by 25
“There are also criteria that the practitioner must fulfill in order to be able to proceed with this therapy: experience in vitreoretinal surgery in children and young adults, experience in subretinal surgery in patients with advanced retinal dystrophy or other retinal-degenerative diseases and avoidance of accumulatio…”
BackgroundKovacs, K. D., Ciulla, T. A., & Kiss, S. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2121646 · Cited by 20
“Given some of the concerns regarding NAbs development, depending on the route of administration, there is also some concern that re-treatments may lead to serially decreasing efficacy or higher rates of inflammation.”
BackgroundInfluentialBiology, Pathobiology and Gene Therapy of CNG Channel-Related Retinopathies
Gerhardt, M. J., Priglinger, S. G., Biel, M., & Michalakis, S. (2023) · Biomedicines · doi:10.3390/biomedicines11020269 · Cited by 26
Self-citationRisk mitigation of immunogenicity: a key to personalized retinal gene therapy
Varin, J., Morival, C., Maillard, N., Adjali, O., & Cronin, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312818 · Cited by 19
Immunology of Retinitis Pigmentosa and Gene Therapy–Associated Uveitis
Yang, P. G., Mustafi, D., & Pepple, K. L. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041305 · Cited by 22
PRPF31-retinitis pigmentosa: Challenges and opportunities for clinical translation
Aweidah, H., Xi, Z., Sahel, J., & Byrne, L. C. (2023) · Vision Research · doi:10.1016/j.visres.2023.108315 · Cited by 21
Pouzolles, M., Machado, A., Guilbaud, M., Irla, M., Gailhac, S., Barennes, P., Cesana, D., Calabria, A., Benedicenti, F., Sergé, A., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.029 · Cited by 17
Gene Therapy for Inherited Retinal Disorders: Update on Clinical Trials
Michalakis, S., Gerhardt, M. J., Rudolph, G., Priglinger, S. G., & Priglinger, C. (2021) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1384-0818 · Cited by 19
“Still, there is some risk due to the invasive subretinal surgery procedure [43] or due to transient immune responses to the vector [10,44].”
BackgroundSelf-citationCreating an Ocular Biofactory: Surgical Approaches in Gene Therapy for Acquired Retinal Diseases
Xu, D. N., Khan, M., & Ho, A. C. (2021) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000362 · Cited by 19
van der Veen, I., Heredero Berzal, A., Koster, C., ten Asbroek, A. L. M. A., Bergen, A. A., & Boon, C. J. F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021267 · Cited by 14
A Fixed-Depth Microneedle Enhances Reproducibility and Safety for Corneal Gene Therapy
Gilger, B. C., Crabtree, E. E., Song, L., Llanga, T., Cullen, M. A., Blanchard, A., Salmon, J. H., Patel, S. R., Zarnitsyn, V. G., & Hirsch, M. L. (2019) · Cornea · doi:10.1097/ico.0000000000002182 · Cited by 14
The clinical safety landscape for ocular AAV gene therapies: A systematic review and meta-analysis
Liu, Z., Zhang, H., Jia, H., Wang, H., Huang, Z., Tang, Y., Wang, Z., Hu, J., Zhao, X., Li, T., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112265 · Cited by 22
“66 A recent study demonstrated that the anterior and posterior compartments of the eye have separate lymphatic drainage systems, with the IVT administration induced more AAV-specific CD8 + T cells in deep cervical lymph nodes and retina, exacerbating the innate immune response to AAV.”
Yang, Z., Yan, L., Zhang, W., Jia, Q., An, W., & Yao, K. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1265630 · Cited by 20
Challenges in AAV-Based Retinal Gene Therapies and the Role of Magnetic Nanoparticle Platforms
Siontas, O., & Ahn, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237385 · Cited by 13
Therapeutic landscape for inherited ocular diseases: current and emerging therapies
Chan, H. W., Oh, J., & Leroy, B. P. (2023) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2022-179 · Cited by 13
“Exposure to NAbs against AAV inducing humoral response* and reducing treatment response[53] AAV vectors need to traverse choroid to”
BackgroundShort, B. G. (2020) · Toxicologic Pathology · doi:10.1177/0192623320946712 · Cited by 12
“For gene therapy with adeno-associated viral (AAV) vectors in cynomolgus monkeys, intravitreal injections are associated with a higher risk of humoral immune responses and a less favorable biodistribution profile with more viral shedding to blood and draining lymphatic tissue, increased off-target deposition, and less…”
BackgroundShining light on CRISPR/Cas9 therapeutics for inherited retinal diseases
Geiger, A., Kennedy, J. G., Staker, L. G., Wensel, T. G., Casson, R. J., & Thomas, P. Q. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101376 · Cited by 11
Casey, G. A., Papp, K. M., & MacDonald, I. M. (2020) · Journal of Ophthalmic and Vision Research · doi:10.18502/jovr.v15i3.7457 · Cited by 15
“[4, 5] An additional barrier to successful transduction of any retinal cells via intravitreal injection is the humoral immune system; intravitreal injection of non-human primates with both the AAV2 and AAV8 serotypes was found to stimulate production of neutralizing antibodies in subjects with and without preexisting…”
BackgroundSchwartz, M. K., Likhite, S. B., Vetter, T. A., Baird, M., McGovern, V. L., Sierra-Delgado, J. A., Mendel, T., Burghes, A. H. M., & Meyer, K. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.05.016 · Cited by 11
Swirski, S., May, O., Ahlers, M. T., Wissinger, B., Greschner, M., Jüschke, C., & Neidhardt, J. (2023) · Cells · doi:10.3390/cells12060955 · Cited by 11
“Compared to subretinal injections, intravitreal injections exhibit a higher risk for intraocular inflammation and humoral immune response [68].”
BackgroundSelf-citationImmune responses in retinal gene therapy: challenges, mechanisms, and future strategies
Ma, Y., & Shen, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1664968 · Cited by 15
DOG) German Society of Ophthalmology (Deutsche Ophthalmologische Gesellschaft, & RG) German Retina Society e. V. (Retinologische Gesellschaft e. V. (2019) · Der Ophthalmologe · doi:10.1007/s00347-019-0906-2 · Cited by 12
“Intraocular administration of the vector outside the subretinal space has unfavorable sequelae in terms of both the therapeutic effect (lower bioavailability in the target tissue) and the risk profile (greater systemic biodistribution) [26, 27].”
BackgroundEnhanced immune responses to vaccine antigens in the corneal stroma
Xia, D., Toy, R., Pradhan, P., Hejri, A., Chae, J. J., Grossniklaus, H. E., Cursiefen, C., Roy, K., & Prausnitz, M. R. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.045 · Cited by 10
Hinsch, V. G., Boye, S. L., & Boye, S. E. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.252 · Cited by 12
“The subretinal space is relatively immune privileged, 8 – 10 which lowers the risk of a humoral immune response, although this advantage can be lost if Figure 1.”
Lim, Y., Campochiaro, P. A., & Green, J. J. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.12.010 · Cited by 10
Gene therapy for age-related macular degeneration: potential, feasibility, and pitfalls
Berkowitz, S. T., & Finn, A. P. (2024) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000001043 · Cited by 9
“Animal models for intra-vitreal GTAU show clinically transient vitritis with persistent increases in þ cells, likely from Volume 35 (cid:1) (cid:1) nonhuman primate models show humoral immune responses to intravitreal but not subretinal viral vectors [59].”
BackgroundImportance of nonhuman primates as a model system for gene therapy development in ophthalmology
Wozar, F., Seitz, I., Reichel, F., & Fischer, M. D. (2022) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1777-5033 · Cited by 6
“This enables a close approximation of potential trial procedures, such as complete vitrectomy, which significantly improves the eventual translation of therapies, whereas smaller body size simplifies breeding and maintenance [6,7, 21,22].”
BackgroundSelf-citationLentiviral delivered aflibercept OXB-203 for treatment of neovascular AMD
Iqball, S., Beck, D. K., Devarajan, G., Khoo, C. P., O’Connor, D. M., Ellis, S., Guzman, E., Mitrophanous, K. A., & Lad, Y. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.07.001 · Cited by 7
How Advanced are Nanocarriers for Effective Subretinal Injection?
Guan, J.-X., Wang, Y.-L., & Wang, J. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s479327 · Cited by 5
“33 SR injection allows the vector to penetrate the dense vitreous body without being diluted.”
MethodGehrke, E. J., Thompson, J. M., Kalmanek, E., Stanley, S. T., Laird, J. G., Bhattarai, S., Lobeck, B., Mayer, S. K., Mahoney, A., Hassan, S., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1302119 · Cited by 4
“elicited lower levels of humoral immune reactions both in mice and in primates (11).”
BackgroundAlemán, T. S., Uyhazi, K. E., Román, A. J., Weber, M. L., O'Neil, E. C., Świder, M., Sumaroka, A., Maguire, K. H., Aleman, E. M., Santos, A. J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.035 · Cited by 8
“…into account our earlier experiments in the Lca5 gt/gt mouse model, 25,26,48 accumulated experience on the use of AAV8 as vector in preclinical 77,81–88 and clinical trial settings, 83,89–92 and testing of two doses (3.0 E10 and 1.0 × E11 vg/eye) in our experiments in non-human primates (NHPs).”
InfluentialDelivery of Genetic Information: Viral Vector and Nonviral Vector Gene Therapies
Gemayel, M. C., Byrne, L. C., Ciulla, T. A., & Sahel, J. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000360 · Cited by 5
DNA- and RNA-based Gene Therapies in Ophthalmology
Ciulla, T. A., Pennesi, M. E., Kiss, S., & Cunningham, E. T. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000359 · Cited by 4
Ross, M., Sade, K., Obolensky, A., Averbukh, E., Desrosiers, M., Rosov, A., Dvir, H., Gootwine, E., Banin, E., Dalkara, D., et al. (2024) · Gene Therapy · doi:10.1038/s41434-024-00495-5 · Cited by 3
(DOG), D. O. G., (BVA), B. D. A. D. E. V., & (RG), R. G. E. V. (2019) · Der Ophthalmologe · doi:10.1007/s00347-019-0885-3 · Cited by 4
Costa-Verdera, H., Jamwal, D., Fabyanic, E., Hippen, A., Salvatore, M., Du, A., Majowicz, A., Markusic, D., Chatterton, J. E., Haurigot, V., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1799327 · Cited by 2
“As expected from previous reports (11), most animals developed anti-AAV2.”
孔令芸, Xin, C., Cheng, M., Ma, S., Zheng, Z., Chen, J., & Zhou, X. (2026) · Eye Discovery · doi:10.1016/j.edisc.2026.100040 · Cited by 2
Clinical and Ocular Inflammatory Inhibitors of Viral-Based Gene Therapy of the Retina
Ohlhausen, M. E., & Conrady, C. D. (2024) · Acta Microbiologica Hellenica · doi:10.3390/amh69030018 · Cited by 2
Ocular toxicity, distribution, and shedding of intravitreal AAV-eqIL-10 in horses
Young, K., Hasegawa, T., Vridhachalam, N., Henderson, N., Salmon, J. H., McCall, T. F., Hirsch, M. L., & Gilger, B. C. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101360 · Cited by 2
Interrogating the dependency of AAV capsids on AAVR for retinal transduction
Hinsch, V. G., Kellish, P. C., Xu, E. M., Fajardo, D., McLaughlin, K., Kiel, K. N., Peterson, J. J., Friend, H. L., Boye, S. L., & Boye, S. E. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201677 · Cited by 1
George, A., Leigh, A., Selzer, E. B., Pfister, T., DeYoung, C., Villasmil, R., Abu-Asab, M. S., Hiriyanna, S., Hwang, P., Sharma, R., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201705 · Cited by 1
“29 Suprachoroidal injection offers several theoretical advantages along with some drawbacks when compared to these other methods of gene therapy delivery.”
Administration of Ocular Gene Therapy
Xu, D. N., Khan, M., Klufas, M. A., & Ho, A. C. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000365 · Cited by 1
(DOG), D. O. G., (RG), R. G. E. V., & (BVA), B. D. A. D. E. V. (2019) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-0899-6601 · Cited by 1
“Empfehlungsgrad: ⇑⇑ ▪ Eine Anreicherung von Luxturna™ im Glaskörperraum und damit das Risiko einer geringeren Bioverfügbarkeit im Zielgewebe und/oder höhere systemische Biodistribution sollen vermieden werden.”
BackgroundEmerging Therapeutic Modalities for Diabetic Retinopathy
Uddin, M. I., & Jayagopal, A. (2020) · Topics in medicinal chemistry · doi:10.1007/7355_2020_101 · Cited by 1
Suprachoroidal Delivery of Subretinal Gene and Cell Therapy
Xu, D. N., Ma, K., & Ho, A. C. (2021) · Springer eBooks · doi:10.1007/978-3-030-76853-9_9 · Cited by 1
Pulman, J., Ren, D., Visticot, L., Malki, H., Yao, Y., Cian, A. D., Ail, D., Concordet, J., Dalkara, D., & Fisson, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.11.693665 · Cited by 2
“This highlights the need to improve CRISPR/Cas9 safety and efficacy in the retina, through constructs, promoter, and vector optimization, and route of delivery ( 36 , 37 ) as we confirmed that the dose is a limiting factor and cannot be infinitely increased.”
Innate Immunity and the Retinal Pigment Epithelium in Gene Therapy for Inherited Retinal Disorders
Casey, G. A. (2021) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-px5t-6n74
Achromatopsia—Rod Monochromacy
Kohl, S., Michalakis, S., & Štingl, K. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197659403.003.0031
Self-citationRetinal Epithelial Neutralization Assay Optimizes AAV Serotype Selection for Ocular Gene Therapy
Li, Y., Chen, Y., Huo, N., Jia, Z., Huang, H., Zhao, Z., Wu, S., & Hou, L. (2025) · Viruses · doi:10.3390/v17070988
“In ocular gene therapy, while localized subretinal injection administration partially circumvents systemic immune responses [12], emerging evidence indicates that intraocular NAb presence may still compromise therapeutic outcomes through vector neutralization in the targeted microenvironment [13].”
One down but many more to go: the state of gene therapy for inherited retinal disease
Tan, T., Sun, C., Poh, S. S. J., Lim, J., Teo, J. X. J., Dey, S., Chua, Z., Guo, J., Wang, Z., Tay, H. G., et al. (2025) · Regenerative Medicine · doi:10.1080/17460751.2025.2571360
El-Kalaani, A. M., ten Brink, J. B., Boon, C. J. F., & Koster, C. (2026) · Gene Therapy · doi:10.1038/s41434-026-00601-9
Gene therapy development for retinal diseases
Reichel, F. F., Bellingrath, J.-S., Király, P., & FISCHER, M. D. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-22212-2.00016-1
Self-citation
Metadata
- Authors
- Reichel, F. F., Peters, T., Wilhelm, B., Biel, M., Ueffing, M., Wissinger, B., Bartz-Schmidt, K. U., Klein, R., Michalakis, S., Fischer, M. D., & for the RD-CURE Consortium
- Affiliations
- University of Tübingen (DE)
- STZ eyetrial (DE)
- Center for Integrated Protein Science Munich (DE)
- University Eye Hospital, University of Tübingen, Tübingen, Germany
- Universitätsklinikum Tübingen (DE)
- University of Oxford (GB)
- Corresponding author
- Fischer, M. Dominik
- ORCID
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2018-04-05
- Volume
- 59
- Issue
- 5
- Pages
- 1910
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2795742690
- Cited by
- 86
- References
- 21
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 11 · 2023: 11 · 2022: 8 · 2021: 19 · 2020: 12 · 2019: 8 · 2018: 1
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion, cc-by)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- anti-drug antibodies, AAV8, subretinal gene therapy, intravitreal gene therapy, humoral immune response, non-human primates, immunosuppression, vector dose, retinal gene therapy
- MeSH terms
- Dependovirus, Animals, Antibodies, Viral, Color Vision Defects, Enzyme-Linked Immunosorbent Assay, Female, Genetic Vectors, Humans, Macaca fascicularis, Male, Retina, Vitreous Body, Genetic Therapy, Capsid Proteins, Cyclic Nucleotide-Gated Cation Channels, Immunity, Humoral, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.